Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology

Importance Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that cannot accurately be diagnosed during life due to the absence of in vivo biomarkers for CTE neuropathology. Objective To evaluate plasma endogenously cleaved microtubule-binding region tau (eMTBR-tau) as a candidate biomarker for CTE tau tangle neuropathology. Design, Setting, and Participants This case series included 21 former American-style football players who completed a blood draw as part of participation in clinical research at Boston University beginning April 17, 2008, and who subsequently died, donated their brain, and had completed autopsy by October 9, 2026. Exposures Plasma eMTBR-tau nucleic acid–linked immunosandwich assay single-plex immunoassay and plasma phosphorylated tau 217 (p-tau217) (SP-X n = 20; Elecsys n = 1). Main Outcomes and Measures CTE status and stage. Cumulative neuropathologic tau burden scores ranged from 0 to 33 (higher scores indicate tau burden; 0, no tau burden). Results Among 21 male brain donors (median age at blood draw, CTE positive: 68 years [IQR, 61-77]; CTE negative: 49 years [IQR, 47-56]), 18 had a neuropathologic diagnosis of CTE. Of these participants, 16 had a diagnosis of high-stage CTE (stage IV = 8, stage III = 8); and 2, of low-stage CTE (stage II = 1, stage I = 1). Five CTE-positive participants had intermediate or high Alzheimer disease neuropathologic change (ADNC). Plasma eMTBR-tau concentration was significantly higher in CTE-positive participants (median, 0.019 pg/mL [IQR, 0.004-0.030]) compared with CTE-negative participants (0.001 pg/mL [IQR, 0.001-0.001]; β = 1.61 [95% CI, 0.51-2.70]). Plasma eMTBR-tau concentrations were highest among CTE-positive participants with comorbid ADNC (0.082 pg/mL [IQR, 0.059-0.131]) and intermediate among those with high-stage CTE without ADNC (n = 11; median, 0.009 pg/mL [IQR, 0.004-0.021]). Plasma eMTBR-tau concentration was significantly higher in high-stage CTE (median, 0.021 pg/mL [IQR, 0.006-0.038]) compared with low-stage CTE (median, 0.001 pg/mL [IQR, 0.001-0.002]; β = 1.79 [95% CI, 0.45-3.13]) or no CTE (median, 0.001 pg/mL [IQR, 0.001-0.001]; β = 1.78 [95% CI, 0.85-2.71]). Differences remained significant after exclusion of 5 cases with comorbid ADNC. Plasma eMTBR-tau concentration was associated with higher cumulative neuropathologic tau burden score across 11 brain regions (β = 0.71 [95% CI, 0.38-1.05]). Plasma p-tau217 concentration was positively associated with eMTBR-tau (β = 0.68 [95% CI, 0.32-1.04]) but was not associated with CTE. P-tau217 concentrations were in the negative range (n = 11) or intermediate range (n = 5) for participants without ADNC copathology. Four participants with ADNC had p-tau217 concentrations in the positive range; and 1, in the intermediate range. Conclusions and Relevance Participants with high-stage CTE had higher concentrations of plasma eMTBR-tau than those with low-stage or no CTE; concentrations were highest among those with CTE and comorbid ADNC. Plasma eMTBR-tau may represent a feasible biomarker candidate for high-stage CTE tau tangle neuropathology. Larger autopsy and clinical validation studies are needed to establish overall diagnostic accuracy and specificity of plasma eMTBR-tau for CTE neuropathology, in addition to the associated prognostic and clinical implications.

Authors

Institutions

Publication Details

Journal
JAMA
Published
2026-11-19
DOI
https://doi.org/10.1001/jama.2026.24780
Primary Topic
Traumatic Brain Injury Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology

Breton Michael Asken, Nicholas James Ashton, Annalise E. Miner, Kelsey J. Goostrey et al.
JAMA
Traumatic Brain Injury Research
article

Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology

Breton Michael Asken, Nicholas James Ashton, Annalise E. Miner, Kelsey J. Goostrey, Joseph N. Palmisano, Thor D. Stein, Christopher J. Nowinski, Ann Carolyn McKee, Jeremy A. Tanner, Eric M. Reiman, Gil Dan Rabinovici, Bobak Abdolmohammadi, Michael Louis Alosco, Daniel Hamed Daneshvar, Rachel L. Nosheny, Martha Elizabeth Shenton, Brett M. Martin, Yorghos Tripodis, Jesse B Mez, Jeffrey L. Cummings, Henrik Zetterberg, Jacob Labonte, Sophia B. Nosek, Matthew Roebuck, Robert A Stern, Alpana Singh, Keaden Morisaki, Abigail Young, Davron Hanley
article en

Abstract

Importance Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that cannot accurately be diagnosed during life due to the absence of in vivo biomarkers for CTE neuropathology. Objective To evaluate plasma endogenously cleaved microtubule-binding region tau (eMTBR-tau) as a candidate biomarker for CTE tau tangle neuropathology. Design, Setting, and Participants This case series included 21 former American-style football players who completed a blood draw as part of participation in clinical research at Boston University beginning April 17, 2008, and who subsequently died, donated their brain, and had completed autopsy by October 9, 2026. Exposures Plasma eMTBR-tau nucleic acid–linked immunosandwich assay single-plex immunoassay and plasma phosphorylated tau 217 (p-tau217) (SP-X n = 20; Elecsys n = 1). Main Outcomes and Measures CTE status and stage. Cumulative neuropathologic tau burden scores ranged from 0 to 33 (higher scores indicate tau burden; 0, no tau burden). Results Among 21 male brain donors (median age at blood draw, CTE positive: 68 years [IQR, 61-77]; CTE negative: 49 years [IQR, 47-56]), 18 had a neuropathologic diagnosis of CTE. Of these participants, 16 had a diagnosis of high-stage CTE (stage IV = 8, stage III = 8); and 2, of low-stage CTE (stage II = 1, stage I = 1). Five CTE-positive participants had intermediate or high Alzheimer disease neuropathologic change (ADNC). Plasma eMTBR-tau concentration was significantly higher in CTE-positive participants (median, 0.019 pg/mL [IQR, 0.004-0.030]) compared with CTE-negative participants (0.001 pg/mL [IQR, 0.001-0.001]; β = 1.61 [95% CI, 0.51-2.70]). Plasma eMTBR-tau concentrations were highest among CTE-positive participants with comorbid ADNC (0.082 pg/mL [IQR, 0.059-0.131]) and intermediate among those with high-stage CTE without ADNC (n = 11; median, 0.009 pg/mL [IQR, 0.004-0.021]). Plasma eMTBR-tau concentration was significantly higher in high-stage CTE (median, 0.021 pg/mL [IQR, 0.006-0.038]) compared with low-stage CTE (median, 0.001 pg/mL [IQR, 0.001-0.002]; β = 1.79 [95% CI, 0.45-3.13]) or no CTE (median, 0.001 pg/mL [IQR, 0.001-0.001]; β = 1.78 [95% CI, 0.85-2.71]). Differences remained significant after exclusion of 5 cases with comorbid ADNC. Plasma eMTBR-tau concentration was associated with higher cumulative neuropathologic tau burden score across 11 brain regions (β = 0.71 [95% CI, 0.38-1.05]). Plasma p-tau217 concentration was positively associated with eMTBR-tau (β = 0.68 [95% CI, 0.32-1.04]) but was not associated with CTE. P-tau217 concentrations were in the negative range (n = 11) or intermediate range (n = 5) for participants without ADNC copathology. Four participants with ADNC had p-tau217 concentrations in the positive range; and 1, in the intermediate range. Conclusions and Relevance Participants with high-stage CTE had higher concentrations of plasma eMTBR-tau than those with low-stage or no CTE; concentrations were highest among those with CTE and comorbid ADNC. Plasma eMTBR-tau may represent a feasible biomarker candidate for high-stage CTE tau tangle neuropathology. Larger autopsy and clinical validation studies are needed to establish overall diagnostic accuracy and specificity of plasma eMTBR-tau for CTE neuropathology, in addition to the associated prognostic and clinical implications.

JAMA
Boston University (US), Brigham and Women's Hospital (US), United States Department of Veterans Affairs (US), University of Nevada, Las Vegas (US), Harvard University (US), The University of Texas at San Antonio Health Science Center (US), University of California, San Francisco (US), Spaulding Rehabilitation Hospital (US), Edith Nourse Rogers Memorial Veterans Hospital (US), Sahlgrenska University Hospital (SE), VA Boston Healthcare System (US), University of Florida (US), Massachusetts General Hospital (US), National Center for PTSD (US), Alzheimer’s Disease Neuroimaging Initiative (US), UK Dementia Research Institute (GB), Banner Sun Health Research Institute (US), National Center for Post Traumatic Stress Disorder (US), Northern California Institute for Research and Education (US), Banner Alzheimer’s Institute (US), UCL Queen Square Institute of Neurology (GB), Concussion & CTE Foundation (US), UCSF Edward and Pearl Fein Memory and Aging Center (US), University College London (GB), University of Gothenburg (SE)
Traumatic Brain Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon